What is the recommended treatment for community-acquired pneumonia?

Treatment of Community-Acquired Pneumonia

For outpatients without comorbidities, treat with a macrolide (azithromycin, clarithromycin, or erythromycin) as first-line therapy; for hospitalized patients on the general ward, use combination therapy with a β-lactam (ceftriaxone or cefotaxime) plus a macrolide (azithromycin); and for ICU patients, use a β-lactam (ceftriaxone, cefotaxime, or ampicillin-sulbactam) plus either azithromycin or a respiratory fluoroquinolone. 1

Outpatient Treatment Algorithm

Previously Healthy, No Risk Factors for Drug-Resistant S. pneumoniae (DRSP)

• First-line: Macrolide monotherapy (azithromycin, clarithromycin, or erythromycin) 1
• Alternative: Doxycycline (weaker evidence) 1

Presence of Comorbidities or DRSP Risk Factors

Risk factors include: chronic heart/lung/liver/renal disease, diabetes, alcoholism, malignancies, asplenia, immunosuppression, or recent antibiotic use (within 3 months) 1

Choose one of:

• Respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin 750 mg) 1
• High-dose amoxicillin (1 g three times daily) OR amoxicillin-clavulanate (2 g twice daily) PLUS a macrolide 1
  • Alternative β-lactams: ceftriaxone, cefpodoxime, or cefuroxime 500 mg twice daily
  • Doxycycline can substitute for the macrolide 1

Critical caveat: In regions where >25% of S. pneumoniae shows high-level macrolide resistance (MIC ≥16 mg/mL), use the comorbidity regimen even for previously healthy patients 1

Inpatient Non-ICU Treatment

Two equally strong options:

1. Respiratory fluoroquinolone monotherapy 1
2. β-lactam PLUS macrolide combination 1

Preferred β-lactams: cefotaxime, ceftriaxone, or ampicillin; ertapenem for selected patients with gram-negative risk factors (excluding Pseudomonas) 1

For penicillin allergy: Use respiratory fluoroquinolone 1

Route of administration: Most hospitalized patients can receive oral antibiotics unless contraindicated (hemodynamic instability, inability to swallow, GI dysfunction) 1, 2

ICU/Severe CAP Treatment

Standard severe CAP:

• β-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) PLUS azithromycin OR a fluoroquinolone 1
• This is a strong recommendation with level I-II evidence 1

For Pseudomonas risk factors (structural lung disease, recent hospitalization, recent broad-spectrum antibiotics):

• Antipseudomonal β-lactam (piperacillin-tazobactam, cefepime, imipenem, or meropenem) PLUS
• EITHER ciprofloxacin or levofloxacin 750 mg
• OR aminoglycoside plus azithromycin
• OR aminoglycoside plus antipneumococcal fluoroquinolone 1

For suspected CA-MRSA (post-influenza, necrotizing pneumonia, hemoptysis):

• Add vancomycin or linezolid 1

For penicillin allergy in ICU: Respiratory fluoroquinolone plus aztreonam 1

Duration of Therapy

The treatment duration should be a minimum of 5 days, with discontinuation only after the patient has been afebrile for 48-72 hours and has no more than one sign of clinical instability. 1, 3

Recent high-quality evidence supports even shorter durations:

• 3 days for patients achieving clinical stability by day 3 (moderate/non-severe CAP) 4, 5
• 5 days for patients stabilized by day 5 3, 4
• 7 days for uncomplicated CAP not meeting earlier stability criteria, and for suspected/proven MRSA or Pseudomonas 3, 4

Clinical stability criteria: Temperature <37.8°C, heart rate <100/min, respiratory rate <24/min, systolic BP ≥90 mmHg, oxygen saturation ≥90%, ability to eat, normal mental status 3

Longer duration needed for: Meningitis, endocarditis, empyema, lung abscess, or if initial therapy was inactive against the identified pathogen 1

Timing and Route Considerations

Emergency department patients: Administer first antibiotic dose while still in the ED 1

IV to oral switch: Transition when hemodynamically stable, clinically improving, able to ingest medications, and GI tract functioning normally 1. This typically occurs within 48-72 hours. Discharge immediately upon clinical stability—do not observe on oral therapy unnecessarily 1

Special Considerations

Influenza co-infection: Test all CAP patients for influenza and COVID-19 when circulating in the community 6. If H5N1 suspected, treat with oseltamivir plus antibacterials targeting S. pneumoniae and S. aureus 1

Severe CAP with septic shock: Consider systemic corticosteroids within 24-36 hours of admission to reduce ARDS risk and mortality 7, 5. Screen for adrenal insufficiency in hypotensive, fluid-resuscitated patients 1

Pathogen-directed therapy: Once reliable microbiological identification obtained, narrow therapy to target the specific pathogen 1

Common Pitfalls to Avoid

1. Do not use macrolide monotherapy for hospitalized patients—combination therapy improves outcomes in severe CAP 1

2. Avoid fluoroquinolone overuse in outpatients to prevent resistance; reserve for specific indications (comorbidities, allergies, treatment failure) 2

3. Do not continue antibiotics beyond clinical stability just to complete an arbitrary course—this increases resistance and adverse effects 3, 4

4. Do not use anti-MRSA or antipseudomonal coverage empirically without specific risk factors—this represents overtreatment since the 2007 HCAP classification was abandoned 3

5. Do not delay switching to oral therapy in stable patients—IV therapy offers no advantage once clinical improvement occurs 1